Cargando…

Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability

OBJECTIVE: To assess access (availability and affordability) to oxytocin and misoprostol at health facilities in Kenya, Uganda and Zambia to improve prevention and management of postpartum haemorrhage (PPH). DESIGN: The assessment was undertaken using data from Health Action International (HAI) rese...

Descripción completa

Detalles Bibliográficos
Autores principales: Kibira, Denis, Ooms, Gaby Isabelle, van den Ham, Hendrika A., Namugambe, Juliet Sanyu, Reed, Tim, Leufkens, Hubert GM, Mantel-Teeuwisse, Aukje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797249/
https://www.ncbi.nlm.nih.gov/pubmed/33414148
http://dx.doi.org/10.1136/bmjopen-2020-042948
_version_ 1783634830063304704
author Kibira, Denis
Ooms, Gaby Isabelle
van den Ham, Hendrika A.
Namugambe, Juliet Sanyu
Reed, Tim
Leufkens, Hubert GM
Mantel-Teeuwisse, Aukje
author_facet Kibira, Denis
Ooms, Gaby Isabelle
van den Ham, Hendrika A.
Namugambe, Juliet Sanyu
Reed, Tim
Leufkens, Hubert GM
Mantel-Teeuwisse, Aukje
author_sort Kibira, Denis
collection PubMed
description OBJECTIVE: To assess access (availability and affordability) to oxytocin and misoprostol at health facilities in Kenya, Uganda and Zambia to improve prevention and management of postpartum haemorrhage (PPH). DESIGN: The assessment was undertaken using data from Health Action International (HAI) research on sexual and reproductive health commodities based on a cross-sectional design adapted from the standardised WHO/HAI methodology. SETTING: Data were collected from 376 health facilities in in Kenya, Uganda and Zambia in July and August 2017. OUTCOME MEASURES: Availability was calculated as mean percentage of sampled medicine outlets where medicine was found on the day of data collection. Medicine prices were compared with international reference prices (IRP) and expressed as median price ratios. Affordability was calculated using number of days required to pay for a standard treatment based on the daily income of the lowest paid government worker. RESULTS: Availability of either oxytocin or misoprostol at health facilities was high; 81% in Kenya, 82% in Uganda and 76% in Zambia. Oxytocin was more available than misoprostol, and it was most available in the public sector in the three countries. Availability of misoprostol was highest in the public sector in Uganda (88%). Oxytocin and misoprostol were purchased by patients at prices above IRP, but both medicines cost less than a day’s wages and were therefore affordable. Availability of misoprostol was poor in rural settings where it would be more preferred due to lack of trained personnel and cold storage facilities required for oxytocin. CONCLUSION: Availability and affordability of either oxytocin or misoprostol at health facilities met the WHO benchmark of 80%. However, countries with limited resources should explore mechanisms to optimise management of PPH by improving access to misoprostol especially in rural areas.
format Online
Article
Text
id pubmed-7797249
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-77972492021-01-21 Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability Kibira, Denis Ooms, Gaby Isabelle van den Ham, Hendrika A. Namugambe, Juliet Sanyu Reed, Tim Leufkens, Hubert GM Mantel-Teeuwisse, Aukje BMJ Open Reproductive Medicine OBJECTIVE: To assess access (availability and affordability) to oxytocin and misoprostol at health facilities in Kenya, Uganda and Zambia to improve prevention and management of postpartum haemorrhage (PPH). DESIGN: The assessment was undertaken using data from Health Action International (HAI) research on sexual and reproductive health commodities based on a cross-sectional design adapted from the standardised WHO/HAI methodology. SETTING: Data were collected from 376 health facilities in in Kenya, Uganda and Zambia in July and August 2017. OUTCOME MEASURES: Availability was calculated as mean percentage of sampled medicine outlets where medicine was found on the day of data collection. Medicine prices were compared with international reference prices (IRP) and expressed as median price ratios. Affordability was calculated using number of days required to pay for a standard treatment based on the daily income of the lowest paid government worker. RESULTS: Availability of either oxytocin or misoprostol at health facilities was high; 81% in Kenya, 82% in Uganda and 76% in Zambia. Oxytocin was more available than misoprostol, and it was most available in the public sector in the three countries. Availability of misoprostol was highest in the public sector in Uganda (88%). Oxytocin and misoprostol were purchased by patients at prices above IRP, but both medicines cost less than a day’s wages and were therefore affordable. Availability of misoprostol was poor in rural settings where it would be more preferred due to lack of trained personnel and cold storage facilities required for oxytocin. CONCLUSION: Availability and affordability of either oxytocin or misoprostol at health facilities met the WHO benchmark of 80%. However, countries with limited resources should explore mechanisms to optimise management of PPH by improving access to misoprostol especially in rural areas. BMJ Publishing Group 2021-01-07 /pmc/articles/PMC7797249/ /pubmed/33414148 http://dx.doi.org/10.1136/bmjopen-2020-042948 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Reproductive Medicine
Kibira, Denis
Ooms, Gaby Isabelle
van den Ham, Hendrika A.
Namugambe, Juliet Sanyu
Reed, Tim
Leufkens, Hubert GM
Mantel-Teeuwisse, Aukje
Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
title Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
title_full Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
title_fullStr Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
title_full_unstemmed Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
title_short Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
title_sort access to oxytocin and misoprostol for management of postpartum haemorrhage in kenya, uganda and zambia: a cross-sectional assessment of availability, prices and affordability
topic Reproductive Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797249/
https://www.ncbi.nlm.nih.gov/pubmed/33414148
http://dx.doi.org/10.1136/bmjopen-2020-042948
work_keys_str_mv AT kibiradenis accesstooxytocinandmisoprostolformanagementofpostpartumhaemorrhageinkenyaugandaandzambiaacrosssectionalassessmentofavailabilitypricesandaffordability
AT oomsgabyisabelle accesstooxytocinandmisoprostolformanagementofpostpartumhaemorrhageinkenyaugandaandzambiaacrosssectionalassessmentofavailabilitypricesandaffordability
AT vandenhamhendrikaa accesstooxytocinandmisoprostolformanagementofpostpartumhaemorrhageinkenyaugandaandzambiaacrosssectionalassessmentofavailabilitypricesandaffordability
AT namugambejulietsanyu accesstooxytocinandmisoprostolformanagementofpostpartumhaemorrhageinkenyaugandaandzambiaacrosssectionalassessmentofavailabilitypricesandaffordability
AT reedtim accesstooxytocinandmisoprostolformanagementofpostpartumhaemorrhageinkenyaugandaandzambiaacrosssectionalassessmentofavailabilitypricesandaffordability
AT leufkenshubertgm accesstooxytocinandmisoprostolformanagementofpostpartumhaemorrhageinkenyaugandaandzambiaacrosssectionalassessmentofavailabilitypricesandaffordability
AT mantelteeuwisseaukje accesstooxytocinandmisoprostolformanagementofpostpartumhaemorrhageinkenyaugandaandzambiaacrosssectionalassessmentofavailabilitypricesandaffordability